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I. INTRODUCTION
Right before our eyes, the rules of the game of life will become
even more complicated. While the prolific English board game publisher
John Wallis theorized there to be seven sequential stages of human life,
this historical chronology will be significantly disrupted with the advent
of three-dimensional (3D) bioprinting. 1 Three-dimensional bioprinting
has provided a means to manufacture living tissues and organs, creating
the fundamental pieces that sustain life. 2 This “game changer” invites
the potential to defy the natural progression of life by enhancing
humans’ overall health, vitality, and average life expectancy.
One of the greatest promises with the arrival of 3D bioprinting is an

* Katherine Smith is a candidate for Juris Doctor at The University of Akron School of Law. She
received her B.S. in Biomedical Engineering and a minor in Applied Mathematics from The
University of Akron.
1. Cornell University, The New Game of Human Life. London: John Wallis, 1790, DIVISION
OF
RARE
&
MANUSCRIPT
COLLECTIONS
(2004),
http://rmc.library.cornell.edu/
games/promoting/4.html (stating that “[t]he New Game of Human Life created by John Wallis
encouraged young players to develop proper moral character, learning the exigencies of the seven
stages of life, from ‘Infancy’ to ‘Dotage,’ while navigating the paths of vice and virtue. Players
advance or forfeit according to the moral nature of the character represented in the square they land
on.”). Charles Hull, Stereolithography (3D Printing), NATIONAL INVENTORS HALL OF FAME (2014),
http://invent.org/inductees/hull-charles/ (Charles W. Hull first invented commercial 3D printing in
1986. His method, which he titled “sterolithography,” involved sequentially printing thin layers of
an ultraviolet cured-material to form a solid 3D structure. 3D bioprinting is the future of this longstanding technology.). Wai Hon Wah, Introduction to STL Format, POLYTECHNICAL UNIVERSITY
HONG
KONG
(1999),
http://download.novedge.com/Brands/FPS/Documents/
OF
Introduction_To_STL_File_Format.pdf (describing standard tessellation language (“STL”) as a
facet-based embodiment that approximates surface and solid items only (points, lines, curves, and
attributes such as layers and color in the CAD system will be ignored during the output process).
Facets delineate the surface of a 3D object. Most 3D printers can only use a model if it has been
exported to STL format.). Sean V. Murphy & Anthony Atala, 3D bioprinting of tissues and organs,
BIOTECHNOLOGY,
773
(2014),
http://www.nature.com/nbt/journal/
NATURE
v32/n8/full/nbt.2958.html (also asserting that “[t]he development of solvent-free, aqueous-based
systems enabled the direct printing of biological materials into 3D scaffolds that could be used for
transplantation with or without seeded cells. The next step was 3D bioprinting as a form of tissue
engineering, made possible by recent advances in 3D printing technology, cell biology and materials
science. A related development was the application of 3D printing to produce medical devices such
as stents and splints for use in the clinic.”).
2. Murphy & Atala, supra note 1 (addressing that “[the] complexities [of bioprinting]
require the integration of technologies from the fields of engineering, biomaterials science, cell
biology, physics and medicine. 3D bioprinting has already been used for the generation and
transplantation of several tissues, including multilayered skin, bone, vascular grafts, tracheal splints,
heart tissue and cartilaginous structures. Other applications include developing high-throughput 3Dbioprinted tissue models for research, drug discovery and toxicology.”).
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answer to expediting the organ donor transplant process. 3 This promise
will help eradicate desperation, despair, and fear of premature death
from patients awaiting organ donations. According to the Organ
Procurement & Transplantation Network (OPTN), there are currently
over 120,000 waiting list candidates in the United States. 4 Also
astonishing is that approximately 21 people die each day waiting for an
organ transplant, a consequence of there being just under 12,000 donors
and stringent regulations. 5 3D bioprinting would provide an ideal
solution to the central issue—the availability of a donor—by eliminating
the issue altogether. Never again would a family member have to
sacrifice a vital organ or someone in the final stages of a fatal disease
have to live with the notion that an organ may not come in time. The
wait time would be little more than the amount of time it would take to
print an organ; patients could be given a near-exact waiting time, putting
their minds and their families’ minds at ease.
Both federal and state legislatures have passed acts that attempt to
provide safe and equitable systems for the allocation, distribution, and
transplantation of donated organs. 6 In 1984, Congress enacted the
National Organ Transplant Act (NOTA), which created the OPTN and
criminalized the exchange of human organs for valuable consideration. 7
3. Tanya Lewis, 3D-Printed Human Embryonic Stem Cells Created for First Time, LIVE
SCIENCE, (Feb. 5, 2013, 8:27 AM ET), http://www.livescience.com/26865-3d-printed-embryonicstem-cells.html (presenting a second consideration: those who do receive transplants run the risk of
unforeseen medical complications and organ rejection. However, 3D bioprinting may solve that
issue as well; it may be able to incorporate a patient’s own stem cells to regenerate a living organ.
Researchers at Heriot-Watt University in Edinburgh have created a cellular printer that uses living
embryonic stem cells as its “ink.” The researchers hope to use this new printing method “to make
3D human tissues for testing new drugs, grow organs, or ultimately print cells directly inside the
body.” Ultimately, rejection would become moot, reducing the number of complications and
accelerating a patient’s recovery time and reentry into their usual routine.).
4. About Us, UNITED NETWORK FOR ORGAN SHARING, http://www.unos.org/about/
index.php (last visited Nov. 30, 2015) (stating that the United Network for Organ Sharing (UNOS)
is a private, non-profit organization that manages the nation’s organ transplant system and maintains
the national registry for organ matching under contract with the federal government.). Organ
Procurement and Transplantation Network, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES,
http://optn.transplant.hrsa.gov (last visited Nov. 30, 2015) (an official U.S. Government website
managed by the Health and Resources Services Administration, U.S. Department of Health &
Human Services).
5. Organ Procurement and Transplantation Network, supra note 4.
6. Legislation and Policy, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES,
http://www.organdonor.gov/legislation/ (last visited Nov. 30, 2015).
7. Selected Statutory and Regulatory History of Organ Transplantation, U.S. DEPARTMENT
OF HEALTH & HUMAN SERVICES, http://organdonor.gov/legislation/legislationhistory.html (last
visited Nov. 30, 2015) (asserting that NOTA also provided for the establishment of the Task Force
on Organ Transplantation, created the Scientific Registry of Transplant Recipients, and formed an
administrative unit within the Department of Health and Human Services to administer all
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Accordingly, under Section 301 of NOTA, any individual convicted of
buying or selling a human organ faces a five-year prison sentence and/or
a sizeable fine. 8 All 50 states have adopted the Uniform Anatomical Gift
Act (UAGA), which explicitly prohibits the purchase and sale of organs
if removal of the organ is intended after death. 9 Notably, some states
have included a provision prohibiting the purchase and sale of organs by
living donors if removal is to occur before death. 10
Consequently, with the introduction of such a capable technology
comes concern for compliance with the law. This Note begins with a
technical discussion of the technology of bioprinting and explains
current engineering techniques and capabilities. Part II contains an indepth survey of federal and state laws governing organ donation,
analyzing the evolution of organ donor law. This part also presents
arguments for and against live donor organ sales and compares and
contrasts policy arguments dealing with the potentiality that a bioprinted
organ will indeed be determined to be “an organ transplant for valuable
consideration.” Part III turns to a discussion of the applicability of
current law to 3D bioprinting, delving into the issue of whether federal
NOTA restrictions will be applied to the sale of 3D bioprinted organs.
This disturbing construction will mean that a manufactured organ will
qualify as a “human organ” under Section 310 of NOTA such that
selling the printed organs would violate the statute. Whether 3D printed
organs would be considered “experimental treatment” is also discussed
for purposes of whether this would present a roadblock to immediate
patient access to manufactured organs. Part IV of this Note identifies the
ethical implications associated with manufactured organs, specifically
the potential for black market operations, and suggests that these
implications may detract from the countless benefits bioprinted organs
could provide. Finally, Part V speculates that 3D printed organs will,
indeed, be construed to qualify as “human organs” under NOTA and that
the NOTA limitations on the sale of human organs will apply to the sale
of 3D bioprinted organs.

activities).
8. FindLaw, Can I Sell an Organ?, THOMSON REUTERS, http://healthcare.findlaw.com/
patient-rights/can-i-sell-an-organ.html (last visited Nov. 30, 2015).
9. Robyn S. Shapiro, Legal Issues in Payment of Living Donors for Solid Organs, 7
CURRENT OPINION ON ORGAN TRANSPLANTATION, 375-79 (2002), available at
http://www.americanbar.org/publications/human_rights_magazine_home/human_rights_vol30_200
3/spring2003/hr_spring03_livingdonors.html.
10. Id.
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II. 3D BIOPRINTING: ITS HISTORY AND ITS PROMISE
This Note begins by discussing the origin and history of 3D
bioprinting. Part II.A explains 3D printing at its basic level and describes
how a 3D printed model is produced. Part II.B provides an overview of
the three main production methods of 3D printing. Part II.C gives
examples of how 3D printing can be applied in various industries. Part
II.D discusses researchers’ goal of printing cells to form functional
tissues and the challenges that come along with doing so. Part II.E
contrasts traditional tissue engineering with 3D bioprinting tissue. Part
II.F explains two methods of 3D bioprinting, extrusion printing and
thermal ink-jet printing, as well as several details to consider when 3D
bioprinting. Part II.G describes and provides examples of present-day
success with manufacturing functional tissues and also discusses the
limits researchers have faced in light of their success. Part II.H
concludes by discussing the current financial state of funding 3D
bioprinting research in light of other medical research and alludes to new
monetary incentives for engaging in 3D bioprinting research.
A. The Basics of 3D Printing
Three-dimensional printing, also known as “rapid prototyping” or
“additive manufacturing,” provides a process for constructing 3D objects
from a digital file known as a computer-aided design (CAD) model. 11 A
CAD model is a digital, 3D representation of a physical object, typically
created through the use of 3D modeling software. Generally, CAD
models can be used for animation or visualization of an object, to make
design changes to a product, to perform dimensional or comparative
analysis of an object, or even for finite element analysis and
computational fluid dynamics analysis. 12 Regarding 3D printing,
11. What
Is
3D
Printing,
THE
3D
PRINTING
ASSOCIATION,
https://www.the3dprintingassociation.com/what-is-3d-printing (last visited Nov. 30, 2015).
12. Almost Everything You Always Wanted to Know About 3D Scanning, DIRECT
DIMENSIONS, http://www.dirdim.com/lm_everything.htm (last visited Nov. 30, 2015). Finite
http://usa.autodesk.com/adsk/servlet/
Element
Analysis,
AUTODESK,
item?siteID=123112&id=17670721 (last visited Nov. 30, 2015) (explaining that “[f]inite element
analysis (FEA) is a computerized method for predicting how a product reacts to real-world forces,
vibration, heat, fluid flow, and other physical effects. Finite element analysis shows whether a
product will break, wear out, or work the way it was designed. It is called analysis, but in the
product development process, it is used to predict what is going to happen when the product is
used.”). Computational Fluid Dynamics (CFD), SOLIDWORKS, http://www.solidworks.com/sw/
products/simulation/computational-fluid-dynamics.htm (last visited Nov. 30, 2015) (detailing
computational fluid dynamics, which “simulates fluid (either liquid or gas) passing through or
around an object. The analysis can be very complex—for example, containing in one calculation
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functional applications of 3D modeling include providing an outlet for
inventorship, producing a repaired version of a damaged object, and
manufacturing items desired on an impulse. 13
CAD models can be produced in one of two ways: using 3D
modeling software or using a 3D scanner. Three-dimensional modeling
software varies from extremely complex, commercial programs, such as
Autodesk’s 3ds Max, to basic, free options like Google’s SketchUp.
While each software possesses a unique user-interface, on an elementary
level, modeling is generally achieved through the use of principal,
drawing, modification, construction, camera, and walkthrough tools for
manipulation of a model in 3D space. 14 Medical professionals regularly
use 3D modeling software to teach medical students surgical procedures
or to show a patient his or her potential “before and after” results prior to
going under the knife.
Three-dimensional scanning characteristically operates by
triangulation of a laser over a stationary object.15 A laser band scans
across the physical subject transfiguring it into a 3D digital file.16 A
relatively novel and robust exercise of 3D scanning capabilities is 3D
facial scanning, which is a critically useful tool for identification and
verification of individuals employed for homeland security. 17
Three-dimensional printers work similarly to inkjet printers in that
they utilize digital files to create a physical transformation of that file by
depositing a selected medium layer-by-layer rather than drop-by-drop. 18
The layers are also blended together in order to create a physical object
that appears cohesive and whole. 19 Each layer can be seen as a thinly
heat transfer, mixing, and unsteady and compressible flows. The ability to predict the impact of
such flows on your product performance is time consuming and costly without some form of
simulation tool.”).
13. Almost Everything You Always Wanted to Know About 3D Scanning, supra note 12.
14. SketchUp, Drawing quickly, TRIMBLE NAVIGATION LIMITED, http://help.sketchup.com/
en/article/115429 (last visited Nov. 15, 2015) (giving an overview of the tools drawing programs
generally use: principal tools are tools that are used a lot to select and modify geometry; drawing
tools are tools used to create geometry; modification tools are tools used to modify existing
geometry; construction tools are tools used to create construction lines or points and document your
model; camera tools are tools used to view geometry; and walkthrough tools are tools to explore
your model).
15. Anselmo Lastra, et al., 3D Scanning for Biometric Identification and Verification,
INSTITUTE FOR HOMELAND SECURITY SOLUTIONS (2010), http://sites.duke.edu/ihss/files/
2011/12/IHSS_Research-Brief_Lastra.pdf.
16. Id.
17. Id.
18. John Patrick Pullen, You Asked: How Does 3-D Printing Work?, TIME (Jan. 16, 2015),
https://time.com/3671722/3d-printing/.
19. Id.
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sliced horizontal cross-section of the eventual object with an
approximate layer thickness of 100 microns. 20 To put that in perspective,
a piece of printer paper is 100 microns thick. 21 However, extremely high
precision 3D printers exist, which can create layers as thin as 16
microns. 22
B. 3D Printing Technologies and Methods
There are various methods of 3D printing with each process adding
layers generally by transferring multiple layers of a material onto a
construction platform, starting with the bottom layer. Three main
methods of 3D printing exist today, namely, selective laser sintering
(SLS), fused deposition modeling (FDM), and stereolithography
(SLA). 23
SLS employs a powerful laser to fuse tiny particles of metal,
plastic, ceramic, or glass into a desired 3D shape. 24 The laser
discriminately combines the powdered material by scanning the crosssections generated by the 3D modeling program on the surface of the
powder bed. 25 Once all cross-sections are scanned, the powder bed is
lowered by one layer thickness. 26 Subsequently, a new layer of material
is added on top of the prior layer, and the process is repeated until the
object is completed. 27
FDM forms each layer of a 3D object by extruding metal or a

20.
21.

Id.
Lucas Mearian, The first 3D printed organ—a liver—is expected in 2014, COMPUTER
WORLD (December 26, 2013 7:05 AM PT), http://www.computerworld.com/article/2486952/
emerging-technology/the-first-3d-printed-organ——a-liver——is-expected-in-2014.html.
22. PolyJet, SOLID CONCEPTS, https://www.solidconcepts.com/technologies/polyjet/ (last
visited Nov. 30, 2015); see also MRSEC Education Group, Size and Scale, UNIVERSITY OF
WISCONSIN-MADISON (2015), http://education.mrsec.wisc.edu/36.htm (stating that “[a] micrometer,
also called a micron, is one thousand times smaller than millimeter. It is equal to 1/1,000,000th (or
one millionth of meter). Things on this scale usually can’t be seen with your eyes. The diameter of a
hair, which is 40-50 microns wide, is very hard to discern without the use of a magnifying glass. A
magnifying glass will help you see a dust mite. Dust mites are usually around 400 microns long.”).
23. Mark Fleming, What is 3D Printing? An Overview, 3D PRINTER,
http://www.3dprinter.net/reference/what-is-3d-printing (noting that “Fused Deposition Modeling”
and its abbreviation, FDM, are trademarked by Stratasys. The company RepRap uses a similar
process but has called it “Fused Filament Fabrication” (FFF) so as to not interfere with Stratasys’s
trademark.).
FRAMEWORK,
24. 3D
Printing.com,
What
is
3D
printing?,
GENESIS
http://3dprinting.com/what-is-3d-printing/#whatitis (last visited Nov. 30, 2015).
25. Id.
26. Id.
27. Id.
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thermoplastic material through a heated nozzle onto a build platform. 28
The nozzle is capable of moving in both horizontal and vertical
directions by a numerically controlled mechanism, directly controlled by
a computer-aided manufacturing software package. 29 Each layer hardens
immediately after it is deposited and bonds to the previous layer to form
the eventual object. 30
SLA, the original method of 3D printing, operates using a liquid
ultraviolet curable photopolymer resin and an ultraviolet laser to build an
object’s layers one by one. 31 The ultraviolet laser beam is used to draw
out the 3D model one layer at a time from the resin. 32 To accomplish
this, the laser beam traces a cross-section of the 3D model on the surface
of the liquid resin. 33 Exposure to the laser light cures and solidifies the
tracing on the resin and fixes it to the layer below. 34 Then, after the
pattern descends by a distance equivalent to the thickness of one layer, a
resin-filled blade glides across it, re-coating it with new liquid resin.35
After the prior layer has been re-coated, the subsequent layer pattern is
traced, joining the previous layer. 36
C. Applications of 3D Printing
The applications of 3D printing are limitless. The robustness of
today’s machines and surplus of material choices accommodate the
imagination, inclusive of design visualization, prototyping, metal
casting, architecture, healthcare, entertainment, and home use. Recent
breakthroughs in 3D printing have been in the in the automotive,
construction, biomedical, and biotechnology industries.
The automotive industry is taking full advantage of the seemingly
endless capabilities of 3D printing. Local Motors, an American
company, printed the first working, electric car at a trade show in
28.
29.

Id.
Id.; see also Clive Ferguson, A History of Numerically Controlled Machine Tools,
(1978),
ACADEMIA
http://www.academia.edu/670021/A_history_of_numerically_controlled_machine_tools (defining
numerical control as “the dimensional and sequential operation of a machine tool by means of coded
numeric information . . . the information is used to cause, at the appropriate time, the movement of
the part or parts being machined and for the tool or tools involved together with, in some cases,
selection of correct speeds, feed rates, etc.”).
30. What is 3D Printing?, supra note 24.
31. Id.
32. Id.
33. Id.
34. Id.
35. Id.
36. Id.
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Chicago. 37 It was completed in just two days and is comprised of only
49 carbon fiber and plastic parts. 38 Additionally, Kevin Czinger, the
Founder and CEO of Divergent Microfactories, Inc., built the first 3D
printed supercar, called “Blade.” 39 The supercar is composed completely
of 3D printed aluminum nodes and carbon fiber connectors, and it
weighs significantly less than one ton, can pump out as much as 700
horsepower, and can accelerate from zero to 60 in a little more than two
seconds. 40 Blade demonstrates 3D printing’s ability to produce products
that can stand up to extreme forces and performance.41
Audi and Kia are also taking advantage of this progressive
technology. 42 While it has not been unusual for automotive companies to
utilize 3D printed parts in prototypes, Audi and Kia are forerunners in
taking it to the next step. 43 Both automotive companies are working
toward including 3D printed parts within production vehicles. Audi is in
the process of streamlining how its 3D printing techniques and
automotive production methods work together so that it can use metal
3D printed parts in actual production, while Kia has introduced 3D
printed parts into a concept car for presentation at the North American
International Auto Show (NAIAS). 44
In construction, Amsterdam’s Dus Architects is revolutionizing the
industry by erecting the first 3D printed house. 45 While the process will
take a total of three years, it will be compiled of 13 rooms made of
interlocking plastic parts.46 The 3D printing of homes will produce great
benefits: zero waste, reduced costs, and completely recyclable parts.47

37. Tracey Kirkland, 3D-printing: American company Local Motors releases world’s first
computer printed car, ABC (October 13, 2014 10:17 AM), http://www.abc.net.au/news/2014-1013/american-company-makes-worlds-first-3d-printed-car/5810234.
38. Id.
39. Eddie Krassenstein, World’s First 3D Printed Supercar is Unveiled, 3D PRINT.COM (June
24, 2015), http://3dprint.com/74810/3d-printed-supercar-blade/.
40. Id.
41. See generally id.
42. Michael Molitch-Hou, Kia Concept SUV Features 3D Printed Parts, 3D Printing
Industry, (January 11, 2016), http://3dprintingindustry.com/2016/01/11/64658/; Tyler Koslow, Audi
Looks to Put 3D Printed Metal End Parts into Their Autos, 3D PRINTING INDUSTRY (November 13,
2015), http://3dprintingindustry.com/2015/11/13/audi-looks-to-put-3d-printed-metal-end-parts-intotheir-autos/.
43. Id.
44. Id.
45. Tom McKay, Major Breakthrough in 3-D Printing Could End One of the World’s
Biggest Issues, MIC NETWORK (Apr. 7, 2014), http://mic.com/articles/87085/major-breakthroughin-3-d-printing-could-end-one-of-the-world-s-biggest-issues.
46. Id.
47. Id.
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This use could also lead to the 3D printing of low-cost temporary
housing for homeless and use of biodegradable materials for festivals. 48
Yale and Oxford Performance Materials (OPM) are collaborating to
benefit biomedical applications that employ 3D printing. 49 Using OPM’s
high performance polyetherketoneketone (PEKK) polymer, the planned
venture includes ten projects comprising a 3D printed PEKK prosthesis
for rib replacement and 3D printed PEKK devices that deliver
therapeutics for improved vertebral fusion. 50
One of the most innovative and progressive areas of 3D printing is
in biotechnology for tissue engineering applications, which has been
referred to as 3D bioprinting, organ printing, or computer-aided tissue
engineering. 51 The latest advances in 3D printing have allowed for the
manufacture of intricate, functional, living tissue from biocompatible
materials, cells, and supporting components. 52 This application of 3D
printing has been useful for regenerative medicine and addressing the
lack of available tissues and organs for transplantation. 53
D. 3D Bioprinting Tissue Engineering
Although 3D printing has long been a tool to generate
biotechnology devices, the present focus of many researchers has been
on printing cells to form functional tissues. 54 The goal of 3D bioprinting,
which has evolved from the amalgamation of early stereolithographic
techniques and breakthroughs in biology, is to produce tissues and
organs suitable for laboratory investigation, disease modeling, and
therapeutics. 55 With large research universities and companies backing
this technology, it is probable that 3D bioprinting will eventually
become one of the principal areas of research and investment in the
upcoming years. 56

48. Id.
49. Bridget Butler Millsaps, Yale University and OPM Collaborate on Ten 3D Printing
Projects to Further Biomedical Applications, 3DPRINT.COM (Oct. 29, 2014),
http://3dprint.com/21912/yale-university-opm-3d-print/.
PERFORMANCE
MATERIALS,
50. Id.
Biomedical
Raw
Materials,
OXFORD
http://www.oxfordpm.com/biomedical_raw_materials.php (last visited Nov. 30, 2015) (defining
PEKK as a biocompatible, thermoplastic polymer used for implantable medical devices).
51. Murphy & Atala, supra note 1.
52. Id.
53. Id.
54. Suraj Kannan, The 3D Bioprinting Revolution, HARVARD SCIENCE REVIEW (May 1,
2014), http://harvardsciencereview.com/2014/05/01/the-3d-bioprinting-revolution/.
55. Id.
56. Id. (identifying Harvard University and Organovo as large supporters of 3D bioprinting).
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Three-dimensional bioprinting presents additional challenges not
seen in non-biological 3D printing applications, including choice of
biocompatible materials, cell types, cell growth and differentiation
factors, and the fragilities associated with living cells and manufactured
tissue. 57 With the help of technologies from the areas of engineering,
biomaterials, cellular biology, physics, and medicine to address those
intricacies, 3D bioprinting has already produced some promising results
such as the generation and transplantation of multilayered skin, bone,
vascular grafts, heart tissue, and cartilage. 58 Other relevant uses include
developing high-throughput 3D bioprinted tissue models for research,
drug discovery, and toxicology. 59
E. Traditional Tissue Engineering Versus Bioprinting
The National Institute of Biomedical Imaging and Bioengineering
has defined tissue engineering as the “practice of combining scaffolds,
cells, and biologically active molecules into functional tissues.” 60 Tissue
engineering aims to assemble functional constructs that repair, preserve,
or improve damaged tissues or entire organs. 61 Traditional tissue
engineering generally follows a top-down approach where cells are
seeded on a scaffold. 62 Despite the fact that this method has resulted in
some of the earliest clinical successes of tissue engineering, it does not
permit sufficient temporal and spatial control of cells and growth factors
seeded in the scaffold. 63 With this constraint, synthesized tissues in
traditional tissue engineering have a limit to their complexity. 64
Three-dimensional bioprinting employs a customized bottom-up
approach where discrete components of the tissue are arranged in such a
fashion to permit formation of compound tissue construction. 65 This is
made possible by CAD, which allows for careful placement of cells,
materials, and morphogens to duplicate the varieties of organization

57. Murphy & Atala, supra note 1.
58. Id.
59. Id.
60. National Institute of Biomedical Imaging and Bioengineering, Tissue Engineering and
Regenerative Medicine, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES,
http://www.nibib.nih.gov/science-education/science-topics/tissue-engineering-and-regenerativemedicine (last visited Nov. 30, 2015).
61. Id.
62. Kannan, supra note 54.
63. Id.
64. Id.
65. Id.
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found in the body. 66 These strategies usually rely on cells’ innate selfassembly and growth factor-driven mechanisms to create the functional
biomimetic tissues. 67
F. Methods and Parameters of 3D Bioprinting
There are two different types of bioprinting methods. These include
extrusion printing (contact) and thermal ink-jet printing (contactless). 68
In extrusion printing, which is the most common method of 3D
bioprinting, filaments are pushed through a nozzle to generate a 3D
structure. 69 Therefore, there is contact between the delivery apparatus
and the “bio-ink.” 70 In thermal ink-jet printing, small ink bubbles are
produced by pulsing current through the heating component of the
printhead. 71 Subsequently, the change in pressure collapses the ink
bubbles and expels the ink from the nozzle. 72 Hence, there is no contact
between the delivery apparatus and the bio-ink. 73
Compared to conventional 3D printing, 3D bioprinting involves
greater complexities. It is vital to take into account several parameters
with the development of 3D bioprinting, such as the resolution of the
printing, material selection (bio-ink), and cell variability. 74 Deciding
which 3D printer to utilize centers on what the desired resolution is. 75
Designing tissues involves macro and micro-scale control; thus, several
methods must be employed to produce both the gross architecture and

66.
67.

Id.
Id.; see also Raphaël Devillard et al., Cell patterning by laser-assisted bioprinting,
METHODS IN CELL BIOLOGY, 2014, at 119, 159-74, available at http://www.ncbi.nih.gov/
pubmed/24439284.
68. Kannan, supra note 54.
69. Id.; see also Cameron J. Ferris et al., Biofabrication: an overview of the approaches used
for printing of living cells, APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2013, at 4243—58,
available at https://www.ro.uow.edu.au/cgi/viewcontent.cgi?article=1580&context=smhpapers.
70. Kannan, supra note 54; Dan Ferber, An Essential Step Toward Printing Living Tissues,
Harvard John A. Paulson School of Engineering and Applied Sciences (February 19, 2014),
https://www.seas.harvard.edu/news/2014/02/essential-step-toward-printing-living-tissues (defining
“bio-ink” as “functional inks with useful biological properties” or “tissue-friendly inks containing
key ingredients of living tissues”).
71. Kannan, supra note 54; see also Xiaofeng Cui et al., Thermal Inkjet Printing in Tissue
Engineering and Regenerative Medicine, RECENT PATENTS ON DRUG DELIVERY AND
FORMULATION, 2012, at 149-55, available at https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3565591.
72. Kannan, supra note 54.
73. Id.
74. Id.
75. Id.
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detailed patterning of cells. 76 Similarly, the selection of bio-ink is
critical. 77 Research and development of new bio-inks has been a high
priority, including hydrogel mixtures and water-based inks. 78
G. Early Successes in Bioprinting
Several research groups have already achieved success with
manufacturing functional tissues, including skin, blood vessels,
cartilage, the bladder, and the uterus. 79 For instance, researchers at the
Scripps Research Institute were able to produce artificial cartilage
comprised of human chondrocytes in a hydrogel. 80 Additionally,
scientists at Cornell University have constructed aortic valve conduits
composed of various cell types and patterned cell distribution. 81
However, these early achievements did not prevail without
challenges. Although these advances have demonstrated how much
potential 3D bioprinting holds, this technology is limited by the same
obstacle as alternative tissue engineering methods: vascularization. 82
Blood vessels are vital for transferring nutrients, oxygen, and wastes
throughout thick tissues; without them cell death is inevitable. 83 Without
vascularization, tissues produced by 3D printing are required to be very
thin, a limitation that has until now barred the creation of larger tissues
and organs. 84
H. Current Ventures in Bioprinting
In February of 2014, the Lewis Lab at the Harvard School of
Engineering and Applied Sciences made an astounding discovery. 85 The
76. Id.
77. Id.
78. Id.
79. Kate Lyons, Humans could be fitted with kidneys made on 3D PRINTERS thanks to
Australian researchers who have already grown miniature organs in labs, ASSOCIATED
NEWSPAPERS, (May 23, 2014 2:08 PM EST), http://www.dailymail.co.uk/sciencetech/article2637158/Humans-fitted-kidneys-3D-printers.html.
80. Kannan, supra note 54; see also About The Scripps Research Institute, THE SCRIPPS
RESEARCH INSTITUTE, (2015), http://www.scripps.edu/about/index.html (stating that the Scripps
Research Institute is a private, nonprofit medical research facility located in California, dedicated to
research and education in biomedical sciences).
81. Kannan, supra note 54; see also Bin Duan et al., 3D Bioprinting of Heterogeneous Aortic
Valve Conduits with Alginate/Gelatin Hydrogels, J. BIOMED MATER RES A, 2013, at 1255-64,
available at https://ncbi.nlm.nih.gov/pmc/articles/PMC3694360.
82. Kannan, supra note 54.
83. Id.
84. Id.
85. Id.
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group used a customized inkhead bioprinter and inventive bio-inks, such
as a gelatin-based ink for the scaffold and two cell-containing inks. 86
Notably, the seemingly most novel portion of the investigation was the
use of a Pluronic-based bio-ink that switches from a solid to a liquid
when cooled below 4o C. 87 Accordingly, the lab was able to produce 3D
constructs with an intricate grid of Pluronic ink, which upon cooling
resulted in liquidification of the Pluronic and creation of channels within
the structure. 88 To convert these channels into vasculature, they were
subsequently endothelialized. 89 The Lewis group used this Pluronic ink
technique to print a construct of human umbilical vein cells, neonatal
dermal fibroblasts, and vasculature. 90 Down the line, a bioreactor could
be utilized for perfusion to allow for nutrient and oxygen flow within the
structure. 91
Organovo, a San Diego-based company, has also begun conquering
the vasculature hurdle. 92 The company stated that it had overcome
vascularization to a degree in its endeavor to print the first functional
liver. 93 They were able to produce liver tissue with a thickness of greater
than 500 microns that could remain in a fully functional state for at least
40 days. 94 In order to create a working liver, various cell types with
different functions must be combined. 95 Among the cell types Organovo
utilized were fibroblasts and endothelial cells. 96 These are important
players for developing a vasculature network, which allowed the
company to print thick tissue with good cell variability. 97
In the future, the production of a fully-operative liver will be a
landmark in 3D bioprinting history because it will prove that 3D printed
tissue is capable of living long enough to test drug efficacy or to be

86. Id.; see also David B. Kolesky et al., 3D Bioprinting of Vascularized, Heterogeneous
Cell-Laden Tissue Constructs, Advanced Materials, May 21, 2014, at 3124-30, available at
https://www.onlinelibrary.wiley.com/doi/10.1002/adma.201305506/abstract.
87. Kannan, supra note 54.
88. Id.
89. Id.
90. Id.
91. Id.
92. Mearian, supra note 21.
93. Id.
94. Id.
95. Id. (describing the cell types making up a human liver. These include Kupffer cells for
removing debris from the blood, stellate cells for regenerating tissue that has died or been injured,
and sinusoidal endothelial cells, which make up the interior surface of blood vessels and lymphatic
vessels.).
96. Id.
97. Id.
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implanted into the body where it can mature. 98
I. The Incentivization of 3D Bioprinting
There is no doubt that the general field of 3D printing is booming.
With the influx of new developments and uses of the technology,
analysts at International Data Corporation, an American market research
firm that specializes in information and consumer technology, forecasted
that worldwide spending on 3D printing would total a mere $2.7 billion
in 2014. 99 However, they expect long-term growth of 29% a year, which
is much greater than the normal trends in manufacturing. 100 Hopeful
analysts at Morgan Stanley predict even faster annual growth of 34%,
which amounts to more than $20 billion in sales by 2020. 101
Funding for whole organ regeneration research is currently less
than $500 million a year in the U.S., while cancer research and
HIV/AIDS research receive $5 billion and $2.8 billion, respectively. 102
While regenerative medicine is seen as the future of healthcare, the field
is presently falling through the cracks. 103 In order to fuel the
development of bioprinted organs, the Methuselah Foundation, a
Virginia-based nonprofit that backs regenerative medicine research,
announced a $1 million prize for the first organization to print a fully
functioning liver. 104 Additionally, the foundation has begun a campaign
to finance research at major research institutions using Organovo’s
patented NovoGen Bioprinting technology. 105
III. THE EVOLUTION OF ORGAN DONOR LAW
Since as early as the 1800s, organ donation has been in existence. 106

98.
99.

Id.
George Anders, HP’s 3D Print Breakthrough Could Push Rivals ‘Out of Business’,
FORBES (Oct.29, 2014 9:30 AM), http://www.forbes.com/sites/georgeanders/2014/10/29/hps-3dprint-breakthrough-could-push-rivals-out-of-business/.
100. Id.
101. Id.
102. Mearian, supra note 21.
103. Id.
104. Id.
105. PRNewswire, Organovo and Methuselah Foundation Announce Funding of Bioprinting
Research at Research Institutions, ORGANOVO (Jul. 24, 2013), http://ir.organovo.com/news/pressreleases/press-releases-details/2013/Organovo-and-Methuselah-Foundation-Announce-Funding-ofBioprinting-Research-at-Research-Institutions/.
106. Timeline of Historical Events Significant Milestones in Organ Donation and
DEPARTMENT
OF
HEALTH
&
HUMAN
SERVICES,
Transplantation,
U.S.
http://www.organdonor.gov/legislation/timeline.html (last visited Dec. 2, 2015).
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In 1869, the first skin transplant was performed. With such a sensitive
exchange, it was foreseeable that in due time laws would be put into
place to regulate this activity. However, it took over a century for the
government to enact federal law to control organ donation and
transplantation. In 1968, the first organ procurement organization, the
New England Organ Bank, was formed. 107 In that same year, the
National Conference of Commissioners on Uniform State Laws drafted
the Uniform Anatomical Gift Act, which established the Uniform Donor
Card as a legal document of gift in all 50 states, identified the types and
priority of individuals who could donate a deceased person’s organs, and
enabled anyone over 18 years old to legally donate his or her organs
upon death. 108 The biggest breakthrough in organ donor law came in
1984, when Congress passed NOTA.
This Note now explores how organ donation has evolved
throughout the decades by way of Congress and in the eyes of the
general public. Part III.A discusses the National Organ Transplant Act,
which is still in effect today and outlawed the selling of human organs
and established the OPTN and Scientific Registry of Transplanted
Recipients. 109 It also provided for grants for the establishment, initial
operation, and expansion of organ procurement organizations. This Part
next discusses the Organ Donation and Recovery Improvement Act,
which expanded the authority of NOTA. Part III.B presents the different
arguments for and against live donor organ sales that the American Bar
Association has presented. This Part explains that these arguments are
applicable to 3D printed organ sales because the technology is intended
to serve the same purpose—to expedite the distribution of organs for
transplantation.
A. Federal Law: National Organ Transplant Act: Section 301 (C.F.R. 42
U.S. Code § 274e)
The field of organ donation and transplantation is one of the most

107. Organ Procurement Organizations, U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES,
http://organdonor.gov/materialsresources/materialsopolist.html (last visited Dec. 2, 2015) (stating
that Organ Procurement Organizations are nonprofit organizations that are “responsible for two
main functions within their designated service area: 1) increasing the number of registered donors,
and 2) coordinating the donation process when actual donors become available”).
108. Id.
109. Id. (explaining that the Organ Procurement and Transplantation Network was created to
ensure fair and equitable allocation of donated organs and the Scientific Registry of Transplanted
Recipients was implemented to conduct an ongoing evaluation of the scientific and clinical status of
an organ transplantation.).
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regulated areas of healthcare today. 110 Both state and federal statutes
have been enacted to attempt to provide the safest and most evenhanded
system for distribution and transplantation of donated organs. 111
As stated above, in 1984 Congress enacted NOTA. This act created
the OPTN, which is run by the United Network for Organ Sharing
(UNOS), a private, non-profit organization under federal contract. 112
Federal regulations promulgated pursuant to NOTA provide a regulatory
framework for the structure and operation of the OPTN where it is
responsible for increasing and ensuring the effectiveness, efficiency, and
equity of organ sharing in the national system of organ allocation and for
increasing the supply of donated organs for transplantation. 113 Section
301 of NOTA prohibits the purchase of organs under subsection (a),
stating that “it shall be unlawful for any person to knowingly acquire,
receive or otherwise transfer any human organ for valuable
consideration for use in human transplantation if the transfer affects
interstate commerce.” 114 Further, under subsection (b) “[a] violator of
this law shall be fined not more than $50,000 or imprisoned not more
than five years, or both.” 115
NOTA explicitly defines the terms “human organ,” “valuable
consideration,” and “interstate commerce.”116 According to the original
Section 301 of the 1984 version of NOTA, “human organ” in Subsection
(c)(1) was defined as the “human kidney, liver, heart, lung, pancreas,
bone marrow, cornea, eye, bone, and skin, and any other human organ
specified by the Secretary of Health and Human Services (HHS) by
regulation.” 117 However, Section 301 has been amended several times
since its enactment. 118 In 1988, Congress broadened the definition by
inserting “any subpart thereof” after the listed organs and expanding the
definition of “human” to include fetuses. 119 Another amendment in
2007, crafted a new definition of “human organ,” which states, “the term
110. Legislation and Policy, supra note 6.
111. Id.
112. Id.
113. Id.
114. National Organ Transplant Act, 42 U.S.C § 274 (1984).
115. Id.
116. Id.
117. Id.
118. Lingyun Kao, Flynn v. Holder, a Narrow Interpretation of National Organ Transplant
Act (NOTA) Reached Positive Policy Effects, THE UNIVERSITY OF HOUSTON LAW CENTER, 3
(2013),
http://www.law.uh.edu/healthlaw/perspectives/2013/
Kao_Flynn%20v.%20Holder,%20a%20Narrow%20Interpretation%20of%20National%20Organ%2
0Transplant%20Act%20(NOTA)%20Reached.pdf.
119. Id.
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‘human organ’ means the human (including fetal) kidney, liver, heart,
lung, pancreas, bone marrow, cornea, eye bone, skin and intestine,
including the esophagus, stomach, small and/or large intestine, or any
portion of the gastrointestinal tract.” 120
However, the Secretary of HHS has since expanded the definition
of human organs by adding vascularized composite allografts to the
covered list of human organs under the OPTN final rule. 121
Subsection (c)(2) of Section 301 does not define “valuable
consideration” in terms of what it is, but rather what it is not. The term
“valuable consideration” under the statute “does not include the
reasonable payments associated with the removal, transportation,
implantation, processing, preservation, quality control, and storage of a
human organ or the expenses of travel, housing and lost wages incurred
by the donor of a human organ in connection with the donation of the
organ.” 122 However, it has been recognized that “the title of a statute or
120. Public Health Service, Department of Health and Human Services Organ Procurement
and Transplantation Network, 42 C.F.R. § 121.13 (2015).
121. Id.; see also Final Rule, OFFICE OF THE FEDERAL REGISTER (2013),
https://www.federalregister.gov/articles/text/raw_text/201/315/731.txt (discussing that a final rule
issued by HHS was responsible for the addition of vascularized composite allografts; the rule went
into effect on July 3, 2014. “The transplant community has referred to the transplants of intact
vascularized body parts such as hands and faces as composite tissue allograft transplants. As tissues,
these components have been under the regulatory jurisdiction of the Food and Drug Administration
(FDA). For the reasons outlined in the NPRM, the Secretary believes that these components, based
on their clinical characteristics, are more characteristic of organs as defined specifically in NOTA
and subsequently by regulation in the case of intestines and blood vessels used in conjunction with
organ transplantation. For the purpose of this regulation, these components are described as
vascularized composite allografts (VCAs) . . . . Pursuant to this rule, for a body part to be defined as
a VCA, it must have all the following characteristics: A body part that is (1) Vascularized and
requires blood flow by surgical connection of blood vessels to function after transplantation; (2)
containing multiple tissue types; (3) recovered from a human donor as an anatomical/structural unit;
(4) transplanted into a human recipient as an anatomical/structural unit; (5) minimally manipulated
(i.e., processing that does not alter the original relevant characteristics of the organ relating to the
organ’s utility for reconstruction, repair, or replacement—examples of minimal manipulation
include cutting, grinding, and shaping of a VCA); (6) for homologous use (i.e., the replacement or
supplementation of a recipient’s organ with an organ that performs the same basic function or
functions in the recipient as in the donor, e.g., a hand from the donor is to be used as a hand in the
recipient); (7) not combined with another article such as a device; (8) susceptible to ischemia and,
therefore, only stored temporarily (e.g., cold storage in preservation medium and intended for
implantation into a recipient within hours of the recovery) and not cryopreserved; and (9)
susceptible to allograft rejection, generally requiring immunosuppression that may increase
infectious disease risk to the recipient.”).
122. National Organ Transplant Act, 42 U.S.C § 274 (1984); see also Change to the Definition
of “Human Organ” Under Section 301 of the National Organ Transplant Act of 1984, OFFICE OF
THE FEDERAL REGISTER (2013), https://www.federalregister.gov/articles/2013/10/02/201324094/change-to-the-definition-of-human-organ-under-section-301-of-the-national-organtransplant-act-of (asserting that Congress’s amendment to Section 301 in 2007 also affected
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section can aid in resolving ambiguity in the legislation’s text.”123
Section 301 is titled “Prohibition of Organ Purchases,” which does not
explicitly mention “valuable consideration.” 124 Thus, Professor Kevin
Marshall suggests that reading Section 301’s text in light of its title
implies that the indistinct phrase “valuable consideration” addresses
organ transfers “that could be considered to involve a ‘purchase,’ rather
than all donations that may involve some exchange.” 125
Subsection (c)(3) of Section 301 defines the term “interstate
commerce.” However, it is defined as prescribed by section 201(b) of
the Federal Food, Drug, and Cosmetic Act. 126 The Food, Drug, and
Cosmetic Act defines “interstate commerce” as “(1) commerce between
any State or Territory and any place outside thereof, and (2) commerce
within the District of Columbia or within any other Territory not
organized with a legislative body.” 127 This subsection of NOTA has
never been amended.
State law also prohibits the sale of organs in compliance with the
Uniform Anatomical Gift Act (UAGA). 128 The initial version of the
UAGA failed to expressly mention commerce in organs. 129 UAGA was
amended in 1987 to bar unambiguously the purchase and sale of organs
removed after death. 130 Although this prohibition does not cover living
donor organ purchases and sales, some states have tailored the 1987
UAGA to include such a provision. 131
B. Arguments for and Against Living Donor Organ Sales
What may be a precursor to 3D bioprinted organ sales is live donor
organ sales. The American Bar Association has presented different
arguments for and against live donor organ sales. These arguments are
applicable to 3D printed organ sales because the technology is intended
Subsection (C)(2) by excluding paired donation from the definition of “valuable consideration”).
123. INS v. Nat’l Ctr. for Immigrants’ Rights, 502 U.S. 183, 189 (1991); see also C. Kevin
Marshall, Legality of Alternative Organ Donation Practices Under § 274e, MEMORANDUM OPINION
FOR THE GENERAL COUNSEL DEPARTMENT OF HEALTH AND HUMAN Services, 41-2 (2007),
http://www.justice.gov/sites/default/files/olc/opinions/attachments/2015/05/29/op-olc-v031p0040.pdf (concluding that in statutory text, “employment” referred to “unauthorized employment,”
in accordance with the heading of § 274e).
124. Marshall, supra note 123.
125. Id.
126. 42 U.S.C § 274.
127. Federal Food, Drug, and Cosmetic Act § 201, 21 U.S.C. § 321 (2015).
128. Shapiro, supra note 9.
129. Id.
130. Id.
131. Id.
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to serve the same purpose—to expedite the distribution of organs for
transplantation. However, because 3D bioprinted organs eliminate the
live donor aspect, it strengthens or weakens any arguments involving the
living donor.
1. Arguments Supporting Live Donor Organ Sales
The weightiest argument in support of live donor organ sales is that
authorizing human organ sales would produce a greater supply of rare
and life-saving resources. 132 Economists’ assertion that barring
compensation for organs lessens supply is strengthened by years of
reports of people’s offers to sell their organs. 133 Thirty years ago during
the NOTA hearings, one man submitted a letter to the U.S. House of
Representatives Subcommittee on Health and the Environment in hopes
of being compensated for his kidney to fund an education. 134 In another
letter, a mother wanted to sell an organ to pay for her daughter’s medical
treatment 135
Another argument is that people should be able to do with their own
body parts whatever they wish.136 Just as police officers, fishermen such
as in “Deadliest Catch,” and steel workers are paid for their dangerous
work, those who selflessly decide to assume the risk to give their organs
to others should also be compensated. 137 Indeed, some contend that
because hospitals, doctors, laboratories, and pharmaceutical companies
charge patients for transplantation-related products and services, it is
unfair for donors not to be compensated. 138
Bolstering each of these arguments is that despite the fact that
transplantation using paid living donors is unlawful, it occurs. Because
of this, it might be better to legalize the practice so that it could be
regulated properly. 139
2. Arguments Against Live Donor Organ Sales
There are five main objections to permitting live donor organ sales.
First is that the organ buyer-seller relationship would be exploitative and

132.
133.
134.
135.
136.
137.
138.
139.

Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
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either cause or amount to an improper commodification of the body. 140
However, in rebuttal to this argument, society allows other exploitative
practices, such as poorly paid labor practices, so why should organ sales
be considered any more morally problematic? 141
Second is that paid organ donation could exclude disadvantaged
people who cannot afford to pay for an organ. 142 A counter to this
argument is that the government or a privately run organization under
governmental control could purchase the organs and then allocate them
in a fair and equitable way. 143 This would allow for compensation to the
donor as well as a carefully regulated system to ensure impartial
distribution.
Third is that live organ donor sales would undercut voluntary organ
donation. 144 There is evidence showing that marketing in human organs
would ultimately destroy people’s present willingness to donate their
organs out of altruism, thereby decreasing the supply of organs. 145 For
example, when blood was first permitted for sale, the overall blood
supply dropped sharply because the decrease in voluntary donations was
larger than the increase in paid donations. 146 However, it is possible for
analogous compensated and charitable situations to coexist, such as
professional social work and charitable social work. 147
Fourth, incentivizing organ donation through compensation would
undermine the autonomy of true donation because of money’s
manipulative and coercive impact. 148 As mentioned above, organ market
supporters have indicated that it is not unusual for society to allow
people to undertake risks for money when they engage in hazardous
occupations such as mining and jockeying. 149 Additionally, people who
donate an organ to a family member may be subject to a higher degree of
coercion than those who sell their organs because of internal pressure
from family members to save a loved one. 150
Finally, payment for organs would place an additional burden on
the organ-recipient by greatly increasing the overall cost of

140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
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transplantation. 151 However, compensation-supporters have argued that
the scarcity of transplantable organs boosts the economic returns
currently produced by transplant programs, and consequently, the
financial incentives for donation would dwindle the overall costs of
transplant procedures. 152
IV. APPLICABILITY OF EXISTING DONOR LAW TO 3D BIOPRINTING
Three-dimensional bioprinting will eventually supply a technology
capable of expediting the organ donor process for waiting list candidates
in dire need of organ transplantation. However, this technology may
present an opportunity for capitalistic minds to exploit that desperation.
Once organs are produced with great certainty of viability and little
expectation of biological rejection, startups could assemble and begin
manufacturing their own organs. While the OPTN is responsible for
effectively distributing and handling donated transplanted organs, this
new technology would override the OPTN-middleman. Taking that into
account, there would be little to stop privately owned companies from
producing their own organs and selling them directly to patients awaiting
transplants.
This Note now turns to the critical questions regarding applicability
of NOTA for 3D bioprinting. Part IV.A analyzes whether organs
produced through 3D bioprinting will be considered “human organs”
and subject to regulation under NOTA and concludes that NOTA will be
applicable to bioprinted organs. Part IV.B examines what types of
consideration received in exchange for a bioprinted organ would be
considered “valuable consideration” under NOTA and concludes that
compensation of any kind will violate NOTA’s prescription against
receipt of “valuable consideration” in exchange for human organs. Part
IV.C discusses the term “interstate commerce” under NOTA, concluding
that an attempt to sell human organs within the United States, even
human organs harvested outside of the United States, affects interstate
commerce. Part IV.D explains whether 3D bioprinted organs would
constitute “experimental treatment” and thus, whether waiting list
candidates could promptly receive manufactured organs or be required
to wait until after the FDA approval process. It concludes that similar to
in-vitro organogensis, 3D bioprinted organs will have to undergo FDA
testing and approval, delaying any immediate promise of organ
transplantation to waiting list candidates. Finally, Part IV.E explores
151.
152.

Id.
Id.
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current organ trafficking and the great potential for black market
operations of bioprinted organs, concluding that by Congress amending
NOTA, it could either assert more control over or avoid such operations.
Because this is a technology that should come to fruition in the near
future, applicable case law is nonexistent. However, there is common
law exploring generally what may fall under the definitions within
Section 301. This precedent can be used to help forecast what problems
may arise with respect to 3D bioprinting. Also explored is whether 3D
bioprinted organs would be perceived as a readily useable human organ
or as an “experimental drug.” The promise of solving the donor problem
would be halted if, like in vitro grown organs, printed organs must
undergo clinical testing.
A. Interpreting Section 301 of NOTA: What Qualifies as a “Human
Organ?”
While Section 301 lists an expanse of “human organs,” there is
little case law interpreting this lexicon. In Flynn v. Holder, the Ninth
Circuit held that the definition of “bone marrow,” which is included
under NOTA’s definition of “human organ,” did not encompass
peripheral blood stem cells obtained through apheresis but only actual
bone marrow extracted by aspiration. 153 In Flynn, the plaintiffs
challenged the constitutionality of NOTA’s ban on compensation for
bone marrow transplants. 154 The Ninth Circuit based its decision wholly
on “statutory interpretation of NOTA, not the plaintiffs’ allegation that
NOTA’s prohibition on selling bone marrow violated the Equal
Protection Clause of the U.S. Constitution, which prohibits the federal
and state governments from denying any person the equal protection of
the law.” 155 The court reasoned that because NOTA does not ban blood
153. Flynn v. Holder, 684 F.3d 852, 855 (9th Cir. 2012). Donating peripheral blood stem
cells, NATIONAL MARROW DONOR PROGRAM, http://bethematch.org/support-the-cause/donatebone-marrow/donation-process/donating-pbsc/ (last visited Dec. 2, 2015) (“Peripheral blood stem
cell (PBSC) donation is one of two methods of collecting blood-forming cells for bone marrow
transplants. The same blood-forming cells that are found in bone marrow are also found in the
circulating (peripheral) blood. PBSC donation is a nonsurgical procedure, called apheresis. The
donation takes place at an experienced blood center or outpatient hospital facility.”). Bone Marrow
Aspiration and Biopsy, CANCER.NET, http://www.cancer.net/navigating-cancer-care/diagnosingcancer/tests-and-procedures/bone-marrow-aspiration-and-biopsy (last visited Dec 2, 2015) (“Bone
marrow aspiration and bone marrow biopsy are short medical procedures that collect a sample of
bone marrow, the spongy tissue inside of bones, so it can be examined. The procedures, which are
often done together, are used to diagnose some cancers, provide specific information about a blood
cancer, or monitor the side effects and effectiveness of chemotherapy.”).
154. Flynn, 684 F.3d at 852.
155. Id. at 865. Glenn Cohen, Selling Bone Marrow—Flynn v. Holder, THE NEW ENGLAND
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donations and peripheral blood stem cell apheresis donation is
essentially the same as a blood donation, it was permissive. 156
The Flynn court concluded that Congress could not have had the
intent to address the apheresis method when it passed NOTA because
the method did not exist at the time. Statutory interpretation was
necessary in order to clarify the meaning of “bone marrow.” Flynn v.
Holder narrowed the meaning of “bone marrow” in NOTA to include
bone marrow obtained only directly, meaning through the aspiration
method. Therefore, if bone marrow is printed directly from a 3D
bioprinter (analogous to the aspiration method), it will likely fall under
the definition of “human organ” of Section 301. However, if a 3D
bioprinter were to use peripheral blood stem cells and subsequently
transform the cells into bone marrow that would seem to circumvent the
meaning of “bone marrow” in the statute in the same way peripheral
blood stem cell apheresis does.
There are institutions currently producing lab-grown organs.
Anthony Atala of Wake Forest has drawn international commendation
for being the first scientist to implant lab-grown bladders in people,
improving their urinary incontinence. 157 He grew the bladders from the
patients’ own urothelial cells to diminish the chance of the organs being
rejected by the patients’ bodies. 158 Atala is now helping a Pennsylvaniabased company called Tengion to conduct more studies of the bladder
with the idea of eventually seeking federal approval to sell the organs
commercially. 159 While this is currently a mere thought, it can be
inferred that the government would consider lab-grown organs to be
“human organs”—hence, revealing why federal approval is needed.
B. Interpreting Section 301 of NOTA: What Qualifies as “Valuable
Consideration?”
Intertwined with the interpretation of “bone marrow” under Section
301 in Flynn v. Holder was what constitutes “valuable consideration.”
The court upheld NOTA’s ban on the sale of body parts for transplant
JOURNAL
OF
MEDICINE
(2012),
http://www.nejm.org/doi/full/10.1056/
NEJMp1114288?viewType=Print.
156. Kao, supra note 118, at 1-2 (“[M]ost bone marrow stem cells are found in the bone
marrow only, but a small number of them, called peripheral blood stem cells, also exist in the
bloodstream.”).
157. Steve Johnson, Lab-grown human organs: Companies lack funding to meet expectations,
SAN JOSE MERCURY NEWS (Dec. 9, 2007 1:50 AM PST), http://www.mercurynews.com/
business/ci_7675722?nclick_check=1.
158. Id.
159. Id.
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against plaintiffs who sought to incentivize bone marrow transplants by
providing valuable consideration (a $3,000 housing subsidy, scholarship,
or charitable donation) to donors. 160 The Ninth Circuit upheld the law,
“without applying heightened scrutiny to the statute, which would be
required if the ban implicated a fundamental right, and found the statute
constitutional after rational basis review.”161 Compensation for
reasonable personal expenses associated with travel and lost wages is
acceptable (as are paired living donor chains, since the 2007 amendment
of NOTA) but any other “valuable consideration” that might incentivize
sources of organs is not. 162
In Richards v. Holder, the Ninth Circuit held that plaintiff did not
have a constitutional right to buy a kidney. 163 In this case, plaintiff
suffered from an end-stage renal disease and offered to pay $50,000 to a
kidney donor to minimize the waiting time for a kidney. 164 Plaintiff
contended that NOTA violated his due process rights and exacted a
taking without just compensation. 165 The court rejected plaintiff’s
contentions with Flynn v. Holder being the persuasive authority. 166 In
Flynn, the court upheld NOTA’s ban on compensation for human
organs, noting that only a rational basis review was appropriate since
NOTA did not involve a fundamental right. 167 The Richards court again
held the right to offer money for the donation of an organ for transplant
not to be fundamental, and therefore, concluded that plaintiff could not
nullify the statute. 168
While Flynn and Richards address the issues of whether the
purchasing of an organ is a fundamental right, they also help clarify
what is meant by “valuable consideration.” Flynn shows that the statute
prohibits compensation of any kind, i.e. charitable, subsidy, or
scholarship. Richards demonstrates that the statute prohibits direct
payment of monies. Accordingly, intent is inconsequential;
compensation is compensation. Therefore, if a 3D bioprinted organ is
considered a “human organ” any form of compensation in exchange for

160.
161.
162.

Flynn, 684 F.3d at 856.
Richards v. Holder, 2014 U.S. Dist. LEXIS 83431, 8 (D. Mass. June 19, 2014).
Michelle Meyer, HHS Proposes Rule to Amend NOTA, Nullify Flynn v. Holder,
HARVARD LAW (Oct. 4, 2013), http://blogs.law.harvard.edu/billofhealth/2013/10/04/hhs-proposesrule-to-amend-nota-nullify-flynn-v-holder/.
163. Richards, 2014 U.S. Dist. LEXIS 83431 at 12.
164. Id. at 3.
165. Id. at 1.
166. Id. at 10.
167. Id.
168. Id. at 12.
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one will violate the statue.
C. Interpreting Section 301 of NOTA: What Qualifies as “Interstate
Commerce?”
There are countless cases discussing the meaning of “interstate
commerce.” However, there has been only one reported case related to
organ trafficking in the United States.169 The district court in United
States v. Wang charged defendants in a one count indictment with
conspiracy to sell human organs for use in human transplants, in
violation of 42 U.S.C. § 274(e). 170 In this case, defendants attempted to
sell human organs from executed Chinese prisoners in the United
States. 171 The indictment was not dropped because the charges set forth a
jurisdictional basis between the alleged conspiracy and interstate
commerce in the United States. 172 The indictment stated that “the overt
acts in furtherance of the alleged conspiracy occurred in the Southern
District of New York and involved plans to sell organs in the United
States.” 173 Further, the court found that it was a part and object of the
conspiracy that the defendants, “unlawfully, willfully and knowingly
would acquire, receive and otherwise transfer organs from executed
Chinese prisoners, for valuable consideration for use in human
transplantation, which transfer would affect interstate commerce.” 174
D. Would 3D Bioprinted Organs Qualify as an Experimental Treatment?
In Abigail Alliance for Better Access to Developmental Drugs v.
Von Eschenbach, the United States Court of Appeals for the District of
Columbia held that terminally ill, mentally competent patients who have
exhausted all government-approved treatments do not have a
fundamental right to experimental drugs that have only passed limited
FDA safety trials. 175 Any government regulation offending this right,

169. Elizabeth Pugliese, Organ Trafficking and the TVPA: Why One Word Makes a Difference
in International Enforcement Efforts, JOURNAL OF CONTEMPORARY HEALTH LAW & POLICY
(2007), http://scholarship.law.edu/cgi/viewcontent.cgi?article=1111&context=jchlp.
170. United States v. Cheng Yong Wang, 1998 U.S. Dist. LEXIS 13481 (S.D.N.Y. Aug. 26,
1998).
171. Id.
172. Id.
173. Id. at 8.
174. Id. at 5.
175. Byron R. Chin, Note, One Last Chance: Abigail Alliance v. von Eschenbach and the
Right to Access Experimental Drugs, 41 U.C. DAVIS L. REV. 1969, 1972 (2008), available at
http://lawreview.law.ucdavis.edu/issues/41/5/notes/41-5_Chin.pdf.

http://ideaexchange.uakron.edu/akronlawreview/vol49/iss3/5

26

Smith: "Transplanting" Organ Donors with Printers

2016]

“TRANSPLANTING” ORGAN DONORS WITH PRINTERS

765

including the FDA approval process, is subject to a rational basis
analysis, under which “only regulations with no demonstrable rational
relationship to a legitimate state interest would be invalid.” 176
It is reasonable for terminally ill patients to want to undertake the
risks associated with participating in a premarket drug study with the
prospect that it could potentially save their lives.177 However, due to the
stringent qualifications for engaging in such a study, many do not meet
the criteria. 178 These difficulties caused plaintiffs’ challenge to the FDA
approval process. 179
To determine whether a fundamental right existed, the court first
applied the Glucksberg test and looked to history and tradition to note
the difference between drug safety and effectiveness. 180 It found that the
absence of government regulation alone failed to establish that the right
was deeply rooted. 181 Because a fundamental right was not implicated,
the Abigail court applied a rational basis standard of review and
determined that “the FDA’s interest in protecting patients from unsafe
drugs bore a rational relationship to the challenged regulations.” 182 Thus,
the court granted the FDA’s motion to dismiss. 183 With this holding, the
court underscored “both the high hurdle that must be cleared to establish
a right as fundamental and the deference due to legislatures in crafting a
balance between the risks and benefits of medical technology where no
fundamental right is implicated.” 184
The persuasive reasoning the court supplies in Abigail applies with
176. Id.
177. Id. at 1981.
178. Id.
179. Id. at 1982.
180. Id. at 1986.
181. Id. at 1987
182. Id. Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495
F.3d 695, 699 (D.C. Cir. 2007) (remarking that “terminally ill patients need not, however, always
await the results of the clinical testing process.” “The FDA and Congress have created several
programs designed to provide early access to promising experimental drugs when warranted. For
example, under the ‘treatment IND’ program, the FDA may approve use of an investigational drug
by patients not part of the clinical trials for the treatment of ‘serious or immediately life-threatening
disease[s]’ if there exists ‘no comparable or satisfactory alternative drug or other therapy’; if ‘[t]he
drug is under investigation in a controlled clinical trial’; and if the drug’s sponsor ‘is actively
pursuing marketing approval of the investigational drug with due diligence.’ The FDA reserves the
right, however, to deny any treatment IND request if (1) the agency believes there is no ‘reasonable
basis’ to conclude that the drug is effective; or (2) granting the request ‘would . . . expose the
patient . . . to an unreasonable and significant additional risk of illness or injury.’ Sponsors may not
profit from any approved treatment IND program and may only ‘recover costs of manufacture,
research, development, and handling of the investigational drug.’”). Id.
183. Id.
184. Richards v. Holder, 2014 U.S. Dist. LEXIS 83431, 11 (D. Mass. June 19, 2014).
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greater force to the plaintiff’s challenge in Richards. In Abigail the law
forbade the use of particular experimental drugs to plaintiffs who were
terminally ill and without any other treatment options.185 By contrast, in
Richards the law afforded plaintiff access to kidney transplants
(although not without limitation), and he was availing himself of
alternative treatment for his disease, specifically dialysis. 186 Following
the “high hurdle” required to implicate a fundamental right established
by the Abigail court, the Ninth Circuit in Richards found the right to
offer cash for a kidney donation for transplant not to be fundamental. 187
Abigail and Richards set forth an interesting distinction. The court
in Abigail found that the terminally ill “do not have a fundamental right
to experimental drugs that have passed [initial phase] clinical testing”
and thus, denied the plaintiffs’ constitutional claim. 188 The Richards
court found that terminally ill individuals have a fundamental right to a
kidney transplant; access was only denied because a transplant cannot be
given in exchange for valuable consideration. This is an important
difference because whether a printed organ qualifies initially as a
“human organ” or an experimental treatment dictates how soon a patient
can receive a transplant. In the future, if the first printed organs are
considered “human organs,” they are immediately ready for implantation
and saving lives. However, if the first printed organs must undergo
clinical testing, and are therefore at that point in time considered
experimental, a patient would not have a fundamental right to the
bioprinted organs until they have progressed past the initial phase of
testing.
Since an organ is created artificially through the use of a 3D printer,
it could be argued either that it is experimental medical treatment or is a
true organ because it functions necessarily the same as a naturally
occurring organ. One way to analyze this new technology is in
comparison to in vitro organogenesis, which was a precursor to 3D
organ printing. 189 This area of development has already progressed into
185. Id. at 10.
186. Id.
187. Id. at 12.
188. Id. at 11.
(Mar.
19,
2012),
189. Definition
of
In
vitro,
MEDICINENET.COM
http://www.medicinenet.com/script/main/art.asp?articlekey=4033 (explaining that in vitro
organogenesis is a method for regenerating organs from stem cells in a test tube or other laboratory
vessel outside of a living organism.); see also Drew Halley, Growing Organs in the Lab,
SINGULARITY UNIVERSITY (June 8, 2009), http://singularityhub.com/2009/06/08/growing-organsin-the-lab/ (stating that this technology requires precise blueprints for each cell-differentiation step
and that this method has already seen some promising results such as the generation of a bladder,
which is in Phase II testing, meaning that it has already been implanted into individuals and studied
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clinical testing, which is a strong indicator that 3D printing will also
have to endure clinical testing, and thus, fits with the court’s holding in
Abigail. It is likely that even if an individual is terminally ill with no
alternative treatment options, a 3D printed organ will not be a treatment
option until it has completed initial clinical testing and proven safe and
effective. 190 This dampens the almost-immediate gratification outlook
for 3D printed organs, since clinical testing can take several years.191
E. Ethical Considerations of 3D Bioprinting
It is quite possible that with the arrival of 3D bioprinting, there will
come black market operations for the purchase of bioprinted organs.
Indeed, Facebook has already been an instrument used for selling black
market organs. 192 While this contemplation hinges on whether a printed
organ is indeed a “human organ,” it is likely that it will be, and
therefore, is a topic that should not be ignored.
A 2012 report from the World Health Organization showed that
more than one human organ is illegally purchased every hour
worldwide, with the majority being kidneys. 193 Donors can include
impoverished villagers, funeral home directors, and even victims of sex-

how the body adapts to it).
190. Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d
695, 698 (D.C. Cir. 2007) (“Clinical testing for safety and effectiveness requires three or sometimes
four phases.). See Food and Drug Administration, Department of Health and Human Services
Investigantional New Drug Application, 21 C.F.R. § 312.21(a)(1) (discussing that Phase I involves
the initial introduction of a new drug into human subjects. A Phase I study usually consists of
twenty to eighty subjects and is “designed to determine the metabolism and pharmacologic actions
of the [new] drug in humans, the side effects associated with increasing doses, and, if possible, to
gain early evidence on effectiveness.”). § 312.21(b) (stating that Phase II studies are “well
controlled” and “closely monitored” clinical trials of no more than several hundred subjects, used to
evaluate both the “effectiveness of the drug for a particular indication” and its “common short-term
side effects and risks.”). § 312.21(c) (explaining that Phase III studies are expanded clinical trials to
“gather the additional information about effectiveness and safety that is needed to evaluate the
overall benefit-risk relationship of the drug and to provide an adequate basis for physician
labeling.”). 21 U.S.C.A. § 355(n)(1) (West, Westlaw through P.L. 114-114 (excluding 114-92, 11494, 114-95 and 114-113) approved 12-28-2015) (noting that to guide the clinical testing process,
Congress has directed the FDA to establish “[s]cientific advisory panels” to “provid[e] expert
scientific advice and recommendations to the Secretary regarding a clinical investigation of a drug
or the approval for marketing of a drug.”).
191. The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, U.S. FOOD
AND DRUG ADMINISTRATION (Nov. 6, 2014), http://www.fda.gov/drugs/resourcesforyou/
consumers/ucm143534.htm.
192. Emily Thomas, Black Market For Organs Reportedly Alive And Well On Facebook, THE
HUFFINGTON POST (Mar. 10, 2014), http://www.huffingtonpost.com/2014/03/10/kidneys-soldonline-facebook-organ-donors_n_4936216.html.
193. Id.
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trafficking or kidnapping. 194 Each of these groups includes people who
have direct access to organs. However, with 3D bioprinting the pool can
expand enormously. There would no longer be such a limitation. Anyone
who could afford to purchase a printer, was appropriately trained, and
had access to appropriate cells could in theory start their own black
market brigade. Bottom-line, anyone with the motivation and time could
establish an unlawful business.
Would this necessarily be a bad thing? If Congress were to amend
NOTA to explicitly allow the selling of manufactured organs under
controlled circumstances, it would eliminate these ethical issues.
Because 3D bioprinting could create a surplus of manufactured organs,
printed organs could be treated like any other living commodity, such as
bananas, trees, and dogs. Notably, there is no law prohibiting the
exchange of a dog for valuable consideration. No lives would have to be
compromised, no family members would have to make sacrifices, and
there would be no concern of atrophy of organ tissue. If a printed organ
were to die, a new one could be printed out.
In theory, once 3D bioprinted organs are widely available, there
would no longer be a use for donated organs for transplant. As a result,
NOTA could be repealed. This would eliminate any confusion over
regulating donated versus manufactured organs, eradicating any concern
for black-market businesses. The process of organ transplantation could
become as basic and routine as a tonsillectomy.
V. CONCLUSION
Section 301 of NOTA prohibits the purchase of human organs
stating that “it shall be unlawful for any person to knowingly acquire,
receive or otherwise transfer any human organ for valuable
consideration for use in human transplantation if the transfer affects
interstate commerce.” This Note concludes that it is likely that selling
3D printed organs would be a federal offense. The court’s treatment of
the aspiration method in Flynn v. Holder and the analysis of federal
approval for lab-grown organs bolsters the interpretation that a
manufactured organ would be considered a “human organ.” The Ninth
Circuit decisions in Flynn v. Holder and Richards v. Holder provide
helpful insight into construction of “valuable consideration” under
NOTA, suggesting that no compensation of any kind could be given in
exchange for a bioprinted organ, including money, subsidies,

194.

Id.
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scholarships, or other charitable donations. Further, the court in Flynn v.
Holder concluded that it is not a deprivation of life and liberty without
due process of law to forbid the purchase of an organ, even under an
end-stage disease situation. Similarly, the definition of “interstate
commerce” under NOTA can be interpreted as commerce between any
state or territory or any place outside thereof (“but only insofar as such
commerce takes place within the United States”). 195 While this does not
cover intrastate commerce, all 50 states have adopted the UAGA that
makes it unlawful to purchase or sell organs within that state. Based on
the definitions provided in Section 301 and common law, it is likely that
selling or purchasing a completed 3D printed organ anywhere in the
United States would violate NOTA.
Unfortunately, the ethical ramifications of 3D bioprinting might
detract from the benefits it promises to offer. While the use of 3D
bioprinting could eventually save lives, until the federal government
approves it, private creation and selling of 3D bioprinted organs would
exacerbate organ selling on the black market. If Congress were to amend
NOTA, however, to allow for the selling and purchasing of 3D printed
organs, this could eliminate such black market activity.
Optimistically, after successful clinical testing and federal approval,
3D bioprinting could ultimately create a surplus of transplantable organs,
and more importantly, make organs a widely available commodity by
eliminating the donor. If John Wallis were to publish the “New, New
Game of Life” today, it would likely include a few, bonus intermittent
stages of life: Maybe an organ transplantation for a body tune-up to
revert back to the prime of your life or a transplantation to escape death.
With 3D bioprinting, the possibilities are endless and ultimately will
allow the game of life to play on.

195. Commerce and Trade Definitions, 15 U.S.C. § 717a (2015) (Although not a part of the
Federal Food, Drug, and Cosmetic Act, this section of the U.S. Code gives further insight into what
Congress likely meant by “any place outside thereof.”).
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